X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs STERLING BIOTECH - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD STERLING BIOTECH LUPIN LTD/
STERLING BIOTECH
 
P/E (TTM) x 16.6 -1.8 - View Chart
P/BV x 3.9 0.1 5,643.0% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 LUPIN LTD   STERLING BIOTECH
EQUITY SHARE DATA
    LUPIN LTD
Mar-16
STERLING BIOTECH
Dec-13
LUPIN LTD/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs2,12711 20,257.1%   
Low Rs1,2943 38,061.8%   
Sales per share (Unadj.) Rs304.126.8 1,134.4%  
Earnings per share (Unadj.) Rs50.4-15.0 -336.9%  
Cash flow per share (Unadj.) Rs60.7-5.5 -1,110.8%  
Dividends per share (Unadj.) Rs7.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs243.854.9 444.2%  
Shares outstanding (eoy) m450.58267.87 168.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.60.3 2,169.7%   
Avg P/E ratio x33.9-0.5 -7,304.8%  
P/CF ratio (eoy) x28.2-1.3 -2,215.7%  
Price / Book Value ratio x7.00.1 5,540.9%  
Dividend payout %14.90-   
Avg Mkt Cap Rs m770,7401,862 41,399.8%   
No. of employees `00016.41.4 1,207.6%   
Total wages/salary Rs m21,077547 3,854.6%   
Avg. sales/employee Rs Th8,379.65,303.3 158.0%   
Avg. wages/employee Rs Th1,289.0403.8 319.2%   
Avg. net profit/employee Rs Th1,388.7-2,959.0 -46.9%   
INCOME DATA
Net Sales Rs m137,0167,181 1,908.1%  
Other income Rs m1,87743 4,406.1%   
Total revenues Rs m138,8937,223 1,922.8%   
Gross profit Rs m37,535947 3,963.9%  
Depreciation Rs m4,6352,543 182.3%   
Interest Rs m4464,377 10.2%   
Profit before tax Rs m34,330-5,931 -578.8%   
Minority Interest Rs m-880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m11,536-1,924 -599.5%   
Profit after tax Rs m22,707-4,007 -566.8%  
Gross profit margin %27.413.2 207.7%  
Effective tax rate %33.632.4 103.6%   
Net profit margin %16.6-55.8 -29.7%  
BALANCE SHEET DATA
Current assets Rs m97,79014,335 682.2%   
Current liabilities Rs m53,87249,809 108.2%   
Net working cap to sales %32.1-494.0 -6.5%  
Current ratio x1.80.3 630.7%  
Inventory Days Days85403 21.0%  
Debtors Days Days121171 71.0%  
Net fixed assets Rs m86,37955,432 155.8%   
Share capital Rs m901268 336.4%   
"Free" reserves Rs m105,73513,935 758.8%   
Net worth Rs m109,84414,701 747.2%   
Long term debt Rs m53,7399,478 567.0%   
Total assets Rs m224,37873,988 303.3%  
Interest coverage x77.9-0.4 -21,957.1%   
Debt to equity ratio x0.50.6 75.9%  
Sales to assets ratio x0.60.1 629.2%   
Return on assets %10.30.5 2,060.1%  
Return on equity %20.7-27.3 -75.9%  
Return on capital %21.2-6.4 -330.0%  
Exports to sales %49.125.9 189.5%   
Imports to sales %7.40.2 4,381.3%   
Exports (fob) Rs m67,2441,860 3,615.7%   
Imports (cif) Rs m10,19912 83,600.8%   
Fx inflow Rs m71,4051,860 3,839.4%   
Fx outflow Rs m17,80725 71,544.0%   
Net fx Rs m53,5981,835 2,921.0%   
CASH FLOW
From Operations Rs m-3,6901,719 -214.7%  
From Investments Rs m-69,434-3,148 2,205.5%  
From Financial Activity Rs m58,1261,426 4,076.2%  
Net Cashflow Rs m-14,998-3 441,117.6%  

Share Holding

Indian Promoters % 46.6 33.9 137.5%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 0.0 -  
FIIs % 31.9 9.9 322.2%  
ADR/GDR % 0.0 16.9 -  
Free float % 10.1 39.3 25.7%  
Shareholders   98,259 21,482 457.4%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   SUVEN LIFE  SHASUN PHARMA  SANOFI INDIA  TTK HEALTHCARE  SUN PHARMA  

Compare LUPIN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Vishal Sikka's Infosys Exit, White House Shake up & Cues to Watch Out Today(Pre-Open)

Indian share markets ended lower on Friday but gained during the overall week. At the closing bell on Friday, BSE Sensex closed lower by 271 points and the NSE Nifty finished down 67 points.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 18, 2017 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - SUN PHARMA COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS